Vascular tone, and thus blood flow to a tissue bed, is regulated by neuronal-, endothelial-, and smooth muscle–dependent mechanisms. The smooth muscle–dependent component, reflecting the increase in arterial tone in response to increasing pressure (the myogenic response), has been appreciated for over 100 yr (Bayliss, 1902). This myogenic response is an important component of cerebral blood flow (CBF) autoregulation, in which cerebral arteries constrict to an increase in blood pressure so as to maintain constant CBF. Elevation of intraluminal pressure leads to smooth muscle membrane depolarization and ultimately activation of voltage-dependent Ca2+ (CaV) channels. This results in the influx of Ca2+ into the cytosol and the initiation of smooth muscle contraction. Dihydropyridine-sensitive, L-type CaV channels, in particular CaV1.2, figure prominently in the development of myogenic tone (Rubart et al., 1996; Knot and Nelson, 1998). Recently, a more nuanced picture has emerged, with T-type channels also playing a role in Ca2+ delivery for constriction over negative membrane potentials (CaV3.1/CaV3.3) or in privileged communication to large-conductance, Ca2+-sensitive K+ (BK) channels to oppose depolarization and constriction (CaV3.2; Harraz et al., 2014). Thus, the triumvirate of CaV1.2, CaV3.2, and CaV3.3 (or CaV3.1 in rats) channels appears to orchestrate the myogenic response to increases in intravascular pressure. However, the majority of these studies have used cerebral arteries from rodents. The specific expression, function, and contribution of CaV channels to arterial tone in human arterial smooth muscle are not known.
Harraz et al. (2015) test a key assumption in the field: that CaV function in rodent arterial smooth muscle of the cerebral circulation is a valid model for assessing CaV function in human arterial smooth muscle in the brain. In this comprehensive study using human cerebral arteries, the authors determine the composition of CaV isoforms, their functional properties, and their contribution to myogenic tone.
CaV channel pharmacology and significance in human disease
CaV channels are five-subunit complexes composed of a pore-forming α1 subunit and accessory α2, β, δ, and γ subunits. CaV channels are segregated into different types depending on Ca2+ current properties of the α1 subunit, exemplified by L-type (“long lasting”) CaV1.1, 1.2, 1.3, and 1.4 channels and T-type (“transient”) CaV3.1, 3.2, and 3.3 channels. L- and T-type CaV channels exhibit different activation and inactivation properties, with L-type channels displaying an activation curve shifted to more positive voltages (Perez-Reyes, 2003; Catterall, 2011). A rich pharmacology is available for manipulating L-type channels, including several therapeutic drugs such as dihydropyridines (e.g., nifedipine) that are capable of selectively inhibiting the channel. Comparatively speaking, pharmacological options for manipulating T-type channels are very limited. One drug, mibefradil, was initially touted as a selective T-type channel antagonist and made a brief appearance on the market before potentially serious drug interactions made it clear that the drug was not selective (Bezprozvanny and Tsien, 1995; Stolberg, 1998).
CaV channels are involved in various human diseases. L-type CaV1 channels have been implicated in Timothy syndrome, cardiac arrhythmias, and autism spectrum disorders, and T-type CaV3 channels are involved in absence seizures, an inherited epileptic syndrome. Overexpression of CaV channels has also been shown to play a role in cancer progression and peripheral diabetic neuropathy (Nelson et al., 2006; Catterall, 2011; Dziegielewska et al., 2014).
CaV function in human cerebral vasculature
Much of what is known about the structure, function, and expression of CaV channels comes from experiments in rodent models, begging the question: do human cerebral arteries behave similarly to cerebral arteries from rodents? Making judicious use of the meager pharmacological tools available (NNC 55-0396 indiscriminately blocks all T-type channel subtypes and is nonselective at higher concentrations, whereas nickel at 50 µM appears to be selective for CaV3.2 channels [Harraz et al., 2014]), Harraz et al. (2015) set out to uncover the functional role of CaV subtypes in regulating arterial tone in human cerebral arteries. These functional analyses were complemented by molecular and biochemical techniques to determine human CaV expression at mRNA and protein levels. All of these experiments used surface (pial) cerebral arteries collected from patients undergoing resection surgery to remove a tumor (glioblastoma or metastasis from another site) or alleviate various forms of epilepsy or seizure.
Directly comparing channel properties in isolated smooth muscle cells (SMCs) from humans, rats, and mice, Harraz et al. (2015) found that inward Ba2+ current density was notably smaller in human SMCs than in rodents. However, the current–voltage relationships of normalized maximal currents were similar, suggesting a common molecular basis. Similar leftward shifts in activation and inactivation curves were seen before and after application of nifedipine, indicative of the presence of both L- and T-type currents in human, mouse, and rat SMCs. Moreover, myogenic responses of human cerebral arteries were similar to previously published findings on rodents (Knot and Nelson, 1998).
Based on the relationship between pressure and diameter in the presence of nifedipine (L-type inhibition) and NNC 55-0396 (T-type inhibition) and the absence of external Ca2+, to minimize Ca2+ entry through all pathways, the authors concluded that L- and T-type channels contribute similarly to tone at 20 and 40 mm Hg, whereas L-type channels dominate at pressures of 60–100 mm Hg. It had been previously shown that graded elevation of intravascular pressure from 20 to 100 mm Hg causes a graded membrane potential depolarization of rat pial arteries from about −60 to −36 mV (Knot and Nelson, 1998), with 40 mm Hg corresponding to about −53 mV. Assuming that the membrane potential of human pial arteries is similar to that of rat arteries, these data collectively suggest that T-type channels have a significant role over a membrane potential range of −60 to −50 mV, a conclusion consistent with results of the authors’ previous study using rodent cerebral arteries (Harraz et al., 2014). One notable difference between the human and rodent findings was that human cerebral arteries use CaV3.3, and not CaV3.1, to accomplish this task. Paradoxically, however, CaV3.2 exerted opposing effects. Harraz et al. (2015) provide evidence that CaV3.2 typically promotes vasodilation through a Ca2+ spark, BK-dependent mechanism (Fig. 1; Harraz et al., 2014). This suggests that the consequences of T-type channel suppression may vary depending on the relative contribution of CaV3.3 and CaV3.2 channels.
Intravital microscopy and in vivo measurements of vessel diameter and red blood cell velocity can be readily applied to animal models but are not generally suited to human experimentation. To circumvent this limitation, Harraz et al. (2015) generated a computer model to mimic a native cerebral arterial surface network based on the architecture, pressurized vessel myography, and electrophysiological data obtained from human tissue. The resulting model provides a starting point for predicting changes in blood flow that will become increasingly useful as more is understood about the degree to which CaV3.3 and CaV3.2 promote or inhibit arterial tone depending on the relative subtype dominance in a given tissue bed. As this information becomes available for various diseases, it may be possible to use the model to discern the appropriate balance of L-type– and T-type–specific drugs necessary to “tune” CaV activity in a given tissue bed.
Paving the way for future studies on human cerebral vasculature
The work of Harraz et al. (2015) accomplishes two important tasks. First, and foremost, it is an impressively detailed study covering a broad range of approaches that include molecular analyses, tissue function, native channel function, and computer modeling in the most difficult of experimental systems: humans. Second, the caveats of the study, mainly its limited, heterogeneous subject population, highlight just how powerful rodent models can be for understanding human disease. By providing the ability to control age, genetic and environmental variability, and sample size, rodent models provide an invaluable tool for testing hypotheses in living systems that cannot otherwise be tested in vitro or in silico. It is notable how much of the data are in agreement with previously reported data from rodent models. In particular, the work of Harraz et al. (2015) in human tissue provides important conformation of their previous findings on divergent roles of CaV3.1 and CaV3.2 in rat cerebral arteries (Harraz et al., 2014), which may have therapeutic implications.
Out of necessity, most investigations on CaV channels have used Ba2+ as a charge carrier to increase current amplitude and have used conventional voltage-clamp protocols to examine activation and inactivation properties. In typical experiments on myogenic tone, pressure is stepped to different levels and held for minutes. Thus, exploring CaV properties under conditions similar to these would require measurement of steady-state currents, which, because of slow inactivation, are likely to be different from those inferred from short conditioning voltage pulses (Rubart et al., 1996). Ca2+-dependent inactivation, which is absent in experiments with Ba2+, provides an additional complicating factor. To better simulate physiology, it would therefore be important to measure steady-state Ca2+ currents through CaV1.2, CaV3.2, and CaV3.3 channels over the membrane potential range (−60 to −36 mV) encompassed by intraluminal pressures of 20–100 mm Hg. Moreover, in vivo membrane potential likely continuously changes in response to the change in intraluminal pressure with each heartbeat. In mice, mean arterial pressure cycles every ∼100 ms, whereas human mean arterial pressure cycles every ∼1,000 ms. Therefore, it is tempting to speculate that differences in the kinetics of CaV3.3 (human) and CaV3.1 (rodent) are responsible for accommodating differences in pulse-pressure profiles in humans and rodents.
The proposed orchestration of Ca2+ influx into cerebral artery SMCs by CaV1.2, CaV3.3, and CaV3.2 channels, which supply Ca2+ over different pressure/membrane potential ranges (CaV1.2 and CaV3.3) and preferentially activate BK channels (CaV3.2), suggests a marvel of subspecialization (Fig. 1). Understanding how CaV3.2 can preferentially communicate with BK channels will be critical to understanding their regulation of cerebral artery tone. Based on the ability of Ni2+ to inhibit Ca2+ spark–activated BK currents, it would appear that CaV3.2 channels reside in a privileged Ca2+ communication complex with ryanodine receptors (RyRs) in the sarcoplasmic reticulum and nearby surface membrane BK channels (Harraz et al., 2014), an arrangement reminiscent of that described for TRPV4 channels–RyRs–BK channels in rat cerebral arteries (Earley et al., 2005). This inferred “nanostructure” cries out for further exploration using super-resolution microscopy. The observed opposing roles of CaV3.2 and CaV3.3 in human cerebral arteries dictates that therapeutic interventions will ultimately require CaV3 subtype–specific modulators, elevating an already challenging pharmacology (Fig. 1).
Studies on human cerebral arteries are constrained by several limitations, including small sample size, heterogeneous populations, and difficulty of obtaining material from healthy individuals. Champions of translational research will laud the basic science rigor with which Harraz et al. (2015) directly approach human physiology. Those with a more basic science bent may bemoan the fact that the tissues were obtained from a small sample of subjects with diseases that may have been the result of perturbations of CaV function or expression. Ultimately, the importance of performing basic research on human tissue takes precedence over such concerns, legitimate though they may be. In the case of the study by Harraz et al. (2015), the novelty of the findings presented is certain to pave the way for future studies.
This work was supported by grants from the National Institutes of Health (P01-HL-095488, R01-HL-121706, and R37-DK-053832), Totman Medical Research Trust, and the Fondation Leducq.
The authors declare no competing financial interests.
Elizabeth M. Adler served as editor.
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).